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A B S T R A C T
Purpose: Three tear supplements were compared for their effects on the signs, symptoms and inflammatory
status of subjects with dry eye disease. Assessments were made before and after both 2 and 4weeks of treatment.
Methods: In this masked, randomized, 3-way crossover trial, eighteen dry eye subjects were recruited. At each
visit, symptoms, tear evaporation rate, stability and osmolarity were measured and tear samples were analyzed
for 7 inflammatory markers, using multiplex immunoassays. The 3 treatments included carboxymethylcellulose-
glycerine-castor oil (CGC), carboxymethylcellulose (CMC) and hydroxypropyl guar (HPG). The CGC and HPG
drops are emulsified lipids; CGC also contains osmoprotectants. The CMC drop is a standard aqueous polymeric
supplement.
Results: Significant improvements were seen in symptoms (OSDI) and tear stability (NITBUT) with all 3 treat-
ments at 4 weeks. At 4 weeks post-CGC, 6 out of 7 biomarkers demonstrated a>25% reduction (in 40% of
subjects). The same reduction (> 25%) was seen in 10% of the subjects for CMC and in none of the subjects for
HPG. No significantly different change to either evaporation rate or tear osmolarity was found following any of
the three treatments.
Conclusions: In this study, the CGC treatment resulted in the greatest reduction in ocular biomarkers of in-
flammation, while all 3 treatments reduced symptoms and improved tear stability. These results indicate that
subject-perceived symptomatic improvements are not necessarily associated with a reduction in objective
measures of inflammation.
1. Introduction
Dry eye disease (DED) is a common ocular condition that presents
with a wide range of signs and symptoms. It has an estimated pre-
valence of between 5 and 30%, depending on the study population
[1–6]. The recent International Dry Eye Workshop (DEWS II 2017) has
established that DED may be caused by numerous factors, including
age, hormonal changes (especially in females), eyelid conditions, sys-
temic conditions and a variety of environmental influences, including
adverse environments and contact lens wear [7–9]. Regardless of
etiology, DED may involve ocular surface inflammation and a loss of the
homeostasis of the tear film [8,10–12]. Research has shown that eva-
porative water loss to leading to tear hyperosmolarity is the primary
cause of the patient’s discomfort, tissue damage and the inflammatory
response [7,13–15]. Tear hyperosmolarity leads to the secretion of in-
flammatory mediators at the ocular surface and detected in the tears
[16,17]. These mediators, in turn, lead to ocular surface damage, i.e.
epithelial cell damage [18].
There is, currently, no “gold-standard” test available for this con-
dition and existing diagnostic tests show poor agreement with patient
symptoms when diagnosing DED [19–25].
Inflammatory biomarker analysis of tear fluids has emerged as a
novel method of quantifying the inflammatory response in DED, with
research demonstrating an increase in the concentration of in-
flammatory protein biomarkers (cytokines and chemokines) in patients
with DED [26–28]. These inflammatory proteins have also been shown
to be related to the signs and symptoms of DED [29,30]. Inflammatory
biomarkers can also be associated with adverse environmental condi-
tions and various inflammatory pathologies, where they have been
proposed as diagnostic markers in allergic eye disease, graft versus host
disease and keratoconus [31–35]. In addition, using cytokine levels as a
measure of the inflammation associated with DED has the advantage of
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being objective. These measures could be used in assessing DED se-
verity, monitoring disease progression and in quantifying treatment
effects [36–38].
As a result of recent advances in the sensitivity of commercial
protein assays (e.g. Multiplex bead arrays), up to 27 biomarkers can be
assessed at picograms per milliliter (pg/ml) levels. Consequently, ana-
lysis can be made of tear samples that are only 1 µl in size [39,40].
However, this technique can be limited by the difficulty in collecting
even, 1 µl, tear samples from DED patients. Furthermore, inter-subject
variability has so-far prevented the establishment of clear cut-off levels
for a positive disease state [37].
While some DED patients may receive anti-inflammatory treatment,
such as steroids or cyclosporine, almost all patients (regardless of the
level of severity) use one or more artificial tear formulations, primarily
to manage symptoms. Numerous clinical trials have reported relief of
symptoms and a reduction in clinical signs with the use of artificial
tears [41–43]. For example, a report compared the effect of two arti-
ficial tear formulations on matrix metalloproteinase-9 (MMP-9) and IL-
6 levels [44]. However, broader clinical investigations of the potential
effects of artificial tear formulations on inflammatory biomarkers have
not been reported.
Tear supplements use a variety of different ingredients with the aim
of compensating for tear film deficiencies in dry eye. These include
soluble polymers (to provide hydration and lubrication), beneficial
electrolytes (essential to the physiological function of the cornea) and
emulsified lipids (to reduce evaporation of the aqueous component of
the tear film). Some formulations also contain small non-electrolytes,
such as polyols or amino acids. These can function as osmoprotectants
to provide protection from the cellular stress caused by hyper-
osmolarity, which is characteristic of dry eye [45,46].
In this study, 2 formulations containing emulsified lipids, one of
which also containing osmoprotectants, were compared to a standard
aqueous polymer formulation. The intention was to compare the effects
of lipid supplementation alone, lipid supplementation plus protective
non-electrolytes and a standard polymeric aqueous formulation, on
inflammatory biomarkers, as well as on the signs and symptoms of DED.
2. Materials and methods
Recruitment for this study was through email and poster adver-
tisements within Glasgow Caledonian University (GCU) and all tests
were carried out at GCU. The targeted group was those with evapora-
tive dry eye (EDE), in order to investigate the potential benefit for the
lipid-based formulations under study. Eighteen (of the 21 recruited) dry
eye subjects (14 female, 4 male and mean age 30 ± 14 years) com-
pleted participation in this study. Dry eye status was confirmed with a
non-invasive tear break-up time (NITBUT) of< 10 s and an Ocular
Surface Disease Index (OSDI) score of> 12. Moreover, when the study
commenced, all subjects had an elevated tear evaporation rate (TER)
f > 33 g/m−2/h [47]. A Schirmer test was also carried out at the
screening visit to establish tear production levels (see Table 1 for
screening visit data). The Schirmer test was performed without anes-
thetic, with the strip placed at the lateral third of the lid margin for
5min. Throughout the study, the more subjectively-symptomatic eye
was investigated or, if there was no perceived difference, then the right
eye was examined. Exclusion criteria included: active ocular allergy;
current contact lens wear; use of any topical ophthalmic drops within
1 week of the screening visit and commencement of the study (initial
wash-out period); ocular surgery within the last 12 months; change/
addition to any chronic systemic medication known to affect tear pro-
duction (including antihistamines, antidepressants, diuretics and cor-
ticosteroids) within 30 days of any visit; systemic disease known to
affect tear production or loss that had been diagnosed or had not been
stable within 30 days of visit.
This was a randomized, repeated-measures study; each subject re-
ceived all 3 treatments over a 14 week period, as shown in Fig. 1. It was
a single-blind study, whereby subjects were masked as to which treat-
ment they were receiving. Subjects were instructed to instill the eye
drops into both eyes and not to use the drops within two hours of each
assessment visit. Subjects were instructed to use the drops 4 times each
day, and given a checklist to ensure compliance.
The tear formulations tested are listed in Table 2 and will be re-
ferred to by abbreviations, for convenience. CGC (Optive Plus™, Al-
lergan) contains the polymer carboxymethylcellulose plus glycerine
and castor oil in an aqueous emulsion. It also includes the protective
osmoprotectants I-carnitine and erythritol. HPG (Systane Balance®,
Alcon) contains propylene glycol, hydroxypropyl guar, and mineral oil
in an aqueous emulsion. CMC (Refresh Contacts®, Allergan) is an aqu-
eous solution containing carboxymethylcellulose without any added
lipid or additional non-electrolytes. All three are indicated for the relief
of symptoms of dry eye conditions.
Ethical approval was granted through GCU's human subjects’ ethics
committee (Biomedical and Vision Sciences sub-committee). Prior to
participation, written informed consent was obtained from each subject
after a full explanation of the procedures involved. The study was
carried out in accordance with the principles detailed in the Declaration
of Helsinki.
The following assessments were carried out at each test visit:
Table 1
Demographic and screening visit data of subjects detailing age, sex, drops used prior to
the study commencing, OSDI score, NITBUT (average of 3 measurements in seconds) and
Schirmer (mm of wetting in 5min).
Subject Age Sex Drop use prior to study OSDI NITBUT Schirmer
1 21 M Guar Gel 18.2 5 27
2 53 F None 33.3 7 0
3 42 M Carmellose+ glycerine 16.7 7 4
4 27 F Sodium hyaluronate 15.0 4 5
5 42 F None 14.6 6 2
6 25 F Sodium hyaluronate 22.9 8 28
7 26 F Hypromellose 22.9 7 20
8 21 F None 18.2 8 28
9 58 F Hypromellose and carbomer 12.5 5 7
10 22 F Sodium hyaluronate 18.2 5 12
11 21 F Hypromellose 20.5 5 7
12 60 M Carmellose+ glycerine 13.6 6 11
13 23 F Carbomer 34.1 8 14
14 20 F Sodium hyaluronate 16.7 7 5
15 20 M None 16.7 6 5
16 20 F Hypromellose 14.6 5 22
17 23 F Sodium hyaluronate 33.3 6 13
18 20 F Sodium hyaluronate 47.7 3 16
Fig. 1. Repeated measures study design as performed. Each subject completed this pro-
gram of visits with a 1 week washout before starting treatment 1 and a 1week washout
between treatments.
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2.1. OSDI questionnaire
The OSDI questionnaire consists of 12 questions grouped into 3
sections: ocular symptoms, vision-related function and environmental
factors [48]. It is designed to assess the patient’s symptoms, and the
impact these symptoms have on day-to-day life [48]. This questionnaire
has been accepted for use in U.S. Food and Drug Administration (FDA)
clinical trials for DED [48–50].
2.2. Tear osmolarity
The Ocusense TearLab Osmometer (TearLab Corporation, USA) was
used to measure tear film osmolarity. Quality control (QC) was carried
out each day that the TearLab was in use, as recommended by the
manufacturers. The TearLab requires a tear sample of 50 nL, which is
collected directly by the test card. A new single-use, sterile test card was
used for each eye of every subject, at each visit. The tip of the test card
was placed against the inferior temporal tear meniscus, near the outer
canthus, and the sample drawn up by passive capillary action.
2.3. NITBUT
The Hir-Cal grid was mounted in a Bausch and Lomb keratometer,
in which the mires had been removed. The gridlines were projected
onto the ocular surface and viewed through the keratometer eyepiece,
with the room lights switched off [51]. The time, in seconds, from a
blink, to the point when the tear film showed any sign of breaking up,
was measured [52].
2.4. Tear fluid cytokine analysis (inflammatory biomarker analysis)
A 1 µl tear sample was taken, from the study eye as determined at
the first visit, from each individual using 1 disposable, sterile, micro-
capillary tube (Drummond Scientific, USA). This small sample has
previously been shown to be sufficient for cytokine analysis [39]. Tear
fluid was collected from the tear prism situated at the outer canthus
area of the eye. This region was chosen as it is a point of tear pooling,
thus allowing for quicker sample collection. Great care was taken to
minimize contact with the ocular surface, in order to avoid reflex
tearing, as the aim was to collect samples of basal (not reflex) tears. The
tear samples were centrifuged with sample diluent and stored at−80 °C
until analysis.
Cytokine analysis was carried out to determine the presence and
concentration of a panel of inflammatory biomarkers in the tears that
have been detected in 1 µl samples [53] (Interleukin-1β (IL-1β), IL-2,
IL-6, IL-8, IL-17, interferon-γ (IFN-γ), tumor necrosis factor-α (TNF-α)),
using a multiplex immunoassay (Bio-Plex Pro Human Cytokine Multi-
plex Assay, Bio-Rad, UK). As this is, to our knowledge, the first time tear
supplements and a panel of biomarkers have been examined in this
way, and due to the inter-subject variability in the concentrations, a
decrease of> 25% in inflammatory biomarker concentration has been
reported as a positive response to treatment. This value was determined
from previous research using anti-inflammatory formulations, where a
change of as little as 22% in biomarker concentration showed statistical
significance, hence this criteria was applied to the current study [40].
2.5. Tear evaporation rate (TER)
TER was measured using temperature and humidity sensors
mounted in one eye-piece of a swimming goggle and linked to a
ServoMed EP-3 Evaporimeter (Servo Med, Sweden) [54]. Two mea-
surements, each lasting 2min, were taken, one with the eye closed and
one with the eye open, in order to account for evaporation from the skin
of the surrounding adnexa within the goggle.
2.6. Corneal staining
The ocular surface was assessed following instillation of a small
amount of sodium fluorescein from a sterile fluorescein impregnated
strip (Mid-Optic, UK). Assessment was performed using a slit lamp with
a cobalt blue filter and a Wratten 12 barrier filter. This allowed for the
clearest view of areas of fluorescence [21]. Grading was determined
using the Oxford scale (Grade 0–5), indicating the level of staining of
the ocular surface [55].
2.7. Statistical analysis
All statistical analysis was carried out using the SPSS Version 21
(SPSS Inc. USA) software package. Descriptive statistics to establish
mean results and standard deviations were performed. Distribution of
the data was assessed using the Kolmogorov-Smirnov test. Repeated
measures analysis of variance (ANOVA) and the Friedman’s test were
used, depending on normality, to compare the effects of the 3 treat-
ments. Appropriate parametric and non-parametric paired samples t-
tests were used to compare pre and post treatment data.
3. Results
A significant improvement (decrease) in the OSDI symptom scores
was noted after 2 weeks of treatment for both the CMC and HPG
treatments (z(17)= 2.7, p=0.004 and t(17)= 4.5, p < 0.001, re-
spectively, Fig. 2). Following 4 weeks of treatment, the improvement in
OSDI scores was found to be significant for all treatments: CGC (t
(17)= 3.0, p=0.008), CMC (z(17)= 3.1, p=0.001) and HPG (t
(17)= 4.9, p < 0.001), see Fig. 2. There was no statistically significant
difference between the treatments.
There was a significant improvement in NITBUT for all 3 treatments
at both 2 weeks and 4weeks (Fig. 3): CGC 2weeks (t(17)= 6.2,
p < 0.001), CGC 4weeks (t(17)= 5.1, p < 0.001), CMC 2weeks (t
(17)= 3.5, p=0.003), CMC 4weeks (t(17)= 5.7, p < 0.001), HPG
2weeks (t(17)= 5.8, p < 0.001) and HPG 4weeks (t(17)= 5.1,
p < 0.001). In the case of NITBUT, an increase in the measurement is
the desired outcome as this indicates increased stability of the tear film.
There was no statistically significant difference between the treatments.
Measurements of TER, tear osmolarity and corneal staining showed
a reduction after 4 weeks for all 3 treatments, however this did not
reach statistical significance (Table 3). A greater reduction in TER was
seen with both the lipid containing-drops compared to the non-lipid
containing drop. The reduction was greatest for the HPG drop
(−11.8 g/m2/h), followed by the CGC drops (−9.1 g/m2/h) and, fi-
nally, the CMC drop (−3.3 g/m2/h). At the outset of this study, the
variance in the TER data was unknown. Following the study, a power
calculation was used to determine the number of subjects needed in
Table 2
Details of the 3 tear formulations, including the abbreviations used.
Name Manufacturer Key ingredients Preservative Abbreviation
Optive Plus™ Allergan, plc Carboxymethylcellulose, glycerine, castor oil, L-carnitine, erythritol Purite® CGC
Refresh Contacts® Allergan, plc Carboxymethylcellulose Purite® CMC
Systane Balance® Alcon, USA Propylene glycol, hydroxypropyl guar, mineral oil Polyquad® HPG
E. Martin et al. Cytokine 105 (2018) 37–44
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order for any change found to reach statistical significance. The result
of this calculation suggests the need to recruit close to 50, rather than
the 18 presented here.
Table 4 shows the baseline cytokine data for each subject (Visit 1).
The average concentrations of the tear fluid inflammatory biomarkers
(pg/ml) were found to be higher in this study than was the case in
other, similar, studies using immunoassay kits from different manu-
facturers [28,30]. This may be due to the small volume collected and
therefore the reduced likelihood of reflex tearing diluting the cytokine
concentrations and/or the different manufacturers of the assay kits.
Table 4 also highlights the inherent variability seen with this technique
(and this patient demographic), as shown by the high SEM values.
Figs. 4 and 5 show the percentage of the subjects who responded to
treatment for each biomarker after 2 and 4weeks of treatment, re-
spectively. A decrease in cytokine concentration (pg/ml) from baseline
of> 25% was deemed a positive response to therapy, as previous re-
search has shown a change of 22% can be significant [40]. After
2 weeks of treatment, the number of subjects exhibiting improvement
while using CGC and CMC were similar, however fewer subjects showed
this benefit when treated with HPG (Fig. 4). After 4 weeks, the CGC
treatment was found to demonstrate a greater positive response rate to
therapy than either of the other two drops (Fig. 5). There was no sta-
tistically significant difference between the 3 arms of the study when
analyzing the percentage change of the biomarkers.
4. Discussion
In the present investigation, the CGC treatment demonstrated the
greatest apparent trend for reducing levels of inflammatory biomarkers.
At 4 weeks post-CGC, 6 out of 7 biomarkers demonstrated a positive
response to treatment (in 40% of subjects). The same positive response
was seen in 10% of the subjects for CMC and in none of the subjects for
HPG. This is consistent with other findings, indicating that formulations
such as CGC (which contain osmoprotectant compounds) may provide
significant reductions in hyperosmolarity-induced cellular stress levels
in cell and animal models (as previously measured by MAP Kinase
signaling molecules, MMPs, and pro-inflammatory cytokine levels)
[46,56,57].
Previous research has indicated that there is no single treatment of
DED that is appropriate for all patients, due to the mixed etiology of the
condition [22,58–60]. Therefore, it seemed logical to analyze the
numbers of subjects who improved with each treatment. Responder
analysis has been used throughout vision research to demonstrate a
treatment effect in conditions such as amblyopia, glaucoma and allergic
eye disease, and a responder index has been proposed for Sjögren
Syndrome [61–64]. Assessing the data in terms of responders versus
non-responders was considered more appropriate than using cytokine
concentration data from all subjects, due to large inter-subject varia-
tions in concentrations (see Table 4) and due to variability observed in
previous literature [30,65]. Additionally, biomarker percentage change
was used as, to date, the biomarker levels that indicate DED are not
known. Nor can it be certain that a subject has a “normal” biomarker
level at the outset, as this level still needs to be established [25].
Therefore, determining if the subject had improved, compared to their
own baseline level, was deemed the most appropriate method to assess
treatment efficacy.
As detailed earlier, a recent report compared the effect of two ar-
tificial tear formulations on MMP-9 and IL-6 levels in humans and
Fig. 2. Change to OSDI score with treatment. Note the zero line is baseline before treatment (probable outliers are represented by the dots) and each box represents the change from
baseline to either 2 or 4 weeks (as shown on the x axis). Key: CGC= carboxymethylcellulose-glycerine-castor oil, CMC= carboxymethylcellulose, HPG=hydroxypropyl guar.
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found that an aqueous formulation with carboxymethylcellulose and
osmoprotectants reduced the level of inflammation [44]. However, the
study assessed MMP-9 and IL-6 staining from impression cytology,
which is a less quantitative method of assessing inflammation, and
examined just 2 pro-inflammatory molecules. If cellular stress is re-
duced by artificial tear treatment, it could be expected that the stimulus
for pro-inflammatory signaling and the subsequent production of in-
flammatory biomarkers may be lower. There may be explanations,
other than there being a direct benefit from the treatment, for the re-
duction in inflammatory biomarkers observed in this study. For ex-
ample, interaction between any one of the components of the CGC
formulation might affect detection of the inflammatory biomarkers in
the tears. Alternatively, interference with the multiplex assay technique
itself, resulting in an apparent reduction in cytokine levels, could also
have occurred. Since there was a minimum time period of 2 h between
Fig. 3. Percentage change to NITBUT with treatment. Note the zero line is baseline before treatment (probable outliers are represented by the asterisk and dots) and each box represents
the change from baseline to either 2 or 4 weeks (as shown on the x axis). Key: CGC= carboxymethylcellulose-glycerine-castor oil, CMC= carboxymethylcellulose, HPG=hydroxypropyl
guar.
Table 3
Mean figures and standard error of mean (SEM) for the clinical parameters measured at
baseline, 2 weeks and 4weeks. All results were non-significant (p > 0.05) when com-
paring baseline with 2 and 4 weeks.
Treatment time CGC CMC HPG
Mean (SEM) Mean (SEM) Mean (SEM)
TER Baseline 82.5 (9.1) 79.5 (6.8) 77.3 (7.2)
2 weeks 77.2 (9.7) 80.8 (10.6) 65.4 (10.3)
4 weeks 73.4 (7.8) 76.2 (10.2) 64.8 (8.5)
Tear osmolarity Baseline 305.3 (2.5) 304.8 (2.4) 307.4 (2.1)
2 weeks 306.1 (2.3) 304.4 (2.7) 305.4 (2.6)
4 weeks 303.6 (2.1) 301.8 (2.4) 302.9 (2.9)
Corneal staining Baseline 1.3 (0.3) 1.5 (0.3) 1.5 (0.2)
2 weeks 0.9 (0.3) 1.1 (0.2) 0.9 (0.2)
4 weeks 1.0 (0.2) 1.0 (0.2) 0.9 (0.2)
Table 4
Cytokine values at baseline (Visit 1) for each subject in picograms per milliliter (pg/ml),
including the average and SEM values.
Subject IL-1β IL-2 IL-6 IL-8 IL-17 IFN-γ TNF-α
1 163 234 548 709 1299 9583 4965
2 1778 1711 2804 2029 13,139 83,388 295,850
3 67 115 233 525 3 7236 1718
4 124 156 309 503 3 7236 3119
5 391 362 716 826 1382 17,823 6511
6 3498 6053 9841 9351 25,067 77,123 58,609
7 2562 4242 7658 7887 9309 45,396 28,047
8 4426 6889 11,702 11,741 27,081 96,921 66,260
9 4017 6671 11,702 14,022 37,354 88,653 69,174
10 808 702 1539 1403 7704 39,767 26,131
11 867 1032 1980 1249 8458 39,767 28,359
12 636 712 889 927 3338 18,895 12,385
13 674 723 1421 1026 6293 30,643 20,254
14 187 168 449 477 1438 6516 2399
15 69 71 197 348 3 1929 1096
16 164 168 380 550 1353 12,189 5217
17 466 395 672 627 5726 21,921 9281
18 339 268 628 477 2947 15,159 6557
Mean 1180 1704 2981 3038 8439 34,452 21,093
SEM 341 573 971 1039 2534 7394 5288
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the use of the drops and tear sampling, such interference is unlikely,
due to the tear turnover rate [47,66]. Castor oil, however, has been
reported to remain on the ocular surface up to 4 h after instillation [67].
Therefore, further research investigating the residency time of the
various components of these eye drops would be beneficial.
A significant improvement in symptoms and NITBUT was observed
for all 3 treatments; however this was not associated with a significant
improvement in the measures of osmolarity, TER and corneal staining,
or in the inflammatory biomarker levels. It is possible that there is a
time lag between the initial symptom relief and improvement in
NITBUT, following regular use of the eye drops, and a corresponding
change to the underlying disease mechanism. As shown in Fig. 2, all
three treatments resulted in a worsening of symptoms for some of the
subjects. This was not surprising, as there is no consensus on which
artificial tear is the most effective in managing signs and symptoms and
it is anecdotally known that different patients with DED prefer different
drops [68].
Previous research using the anti-inflammatory formulations cy-
closporine A and methylprednisolone has shown a significant im-
provement in inflammatory biomarker levels in the conjunctiva, after
3months of treatment [69]. While our current study also demonstrated
reduced inflammatory biomarkers in response to treatment, it is possible
that a longer treatment period is required to achieve a statistically
significant effect on cytokine levels with artificial tears. The apparent
reduction in biomarker levels after 2–4weeks of treatment does sug-
gest, however, that osmoprotectants have a more rapidly-acting me-
chanism than anti-inflammatory medications. For example, a rapid re-
sponse has been shown for over-the-counter tear formulations after only
2 weeks treatment, in a murine model of dry eye (for corneal staining
and goblet cell density) [57]. Moreover, a longer treatment period
(3months) has shown statistically significant reductions in clinical
measures such as TER, osmolarity and corneal staining with artificial
tears [70]. It may be that over a longer time course, a significant re-
duction will also be seen in the inflammatory biomarkers. Further re-
search, following these parameters for a longer period of time, e.g.
3 months, is therefore necessary. This would facilitate examination of
the time course of the inflammatory biomarkers during treatment.
It should be noted that all of these drops contained preservatives,
although the preservatives varied. The CGC and CMC drops contained
Purite®, a stabilized oxychloro complex (SOC), which breaks down into
natural tear components (water, oxygen, sodium and chloride ions) on
contact with the ocular surface [71]. In animal studies, Purite® has been
shown to cause minimal epithelial erosion, when compared to Poly-
quad® (the preservative in the HPG formulation), which is a detergent-
type preservative that may cause corneal epithelial erosion [71]. It is
possible that Polyquad® contributed to the poorer response of the HPG
formulation, as it has been shown, in some studies, to induce an in-
flammatory reaction in cultured human corneal cells [72]. Conversely,
other research found the opposite effect with Polyquad® showing good
tolerability on human corneal cells [73]. Another study in an animal
wound-healing model has suggested that Purite-preserved eye drops
may have some deleterious effects on the ocular surface [74], and in a
clinical study of Purite-preserved drops vs a similar formulation
without preservative, small differences were detected in favor of the
non-preserved drop [75]. It is certainly possible that some of the results
of the present study were influenced by the presence of the pre-
servative. However, due to the inconclusive results of previous research
and lack of dry eye studies, further work investigating these pre-
servatives in vivo would be valuable [76].
It is also important to consider the inclusion criteria
(NITBUT < 10 s and OSDI > 12) employed in this study, as the
average NITBUT of the subjects at baseline was 5.7 (± 1.2) s and the
OSDI was 23 (± 12.8). The NITBUT indicates that the subjects enrolled
in the study were generally of mild/moderate disease severity [10,77].
Therefore, it should be considered how likely a significant improve-
ment, in both clinical and cytokine measures would be. In other words,
is there scope for significant improvements, when the disease is of the
mild/moderate severity? Moreover, as NITBUT was used as a clinical
measure for inclusion, it is likely the subjects’ DED may be more eva-
porative in nature. Several different clinical variables (as well as age,
sex and treatment order) were examined to see if patterns were present
in those who responded to the CGC treatment. One possible link related
to the tear production, as measured by the Schirmer test. This measure
was, generally lower amongst CGC responders, with an average of
9mm, versus 14mm for those who did not respond indicating that the
responders were more aqueous deficient in nature. It should be noted
that 10mm of wetting is a commonly used upper limit for aqueous
deficient dry eye [25,78]. This combination of different signs and
symptoms is reflective of what commonly presents to ophthalmic
clinicians and directly relates to the complex etiology of DED. This
suggests that further research investigating the different sub-groups of
DED would help to improve the treatments currently used in practice to
Fig. 4. Percentage “responders” (decrease in biomarker concentration> 25%) for each
treatment after 2 weeks of eye drop use. Key: CGC= carboxymethylcellulose-glycerine-
castor oil, CMC= carboxymethylcellulose, HPG=hydroxypropyl guar.
Fig. 5. Percentage “responders” (decrease in biomarker concentration> 25%) for each
treatment after 4 weeks of eye drop use. Key: CGC= carboxymethylcellulose-glycerine-
castor oil, CMC= carboxymethylcellulose, HPG=hydroxypropyl guar.
E. Martin et al. Cytokine 105 (2018) 37–44
42
reduce symptoms and levels of inflammation. It must also be ac-
knowledged that this was a relatively young DED subject group
(30 ± 14 years) and therefore a similar study on a group of older
subjects, where DED is more prevalent, would be of significant interest.
5. Conclusions
In conclusion, of the 3 products tested, the eyedrop containing a
polymeric lubricant, emulsified lipid and osmoprotective non-electro-
lytes appeared to be the most effective in reducing DED-associated tear
film inflammatory biomarkers. This finding is supportive of the concept
that improving the ocular surface environment is likely to reduce ocular
pro-inflammatory cytokine activation.
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